Dermatology Phase 3 Readout Calendar

Industry-sponsored dermatology trials with primary completion in the next 12 months or last 12 months.

Data last updated July 17, 2026 · source: ClinicalTrials.gov

Pro feature

All areas Oncology Immunology Metabolic CNS Cardiovascular Infectious Disease Respiratory Rare Disease OphthalmologyDermatologyMusculoskeletal Renal Pain

Next 6 months

Next 12 months

Results posted

Phase 3 Dermatology

What you can answer with this page

A confidence-graded calendar of every industry Phase 3 dermatology trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.

What dermatology trials are reading out soon?

The "upcoming" section shows industry-sponsored Phase 3 dermatology trials with primary completion ahead, soonest first, each graded by how credible that date is.

Which dermatology trials have already read out?

The "recently read out" section shows Phase 3 dermatology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.

How are these readout dates sourced?

Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.

Where can I see readouts for other therapeutic areas?

The full cross-area calendar is on the main readout calendar; this page is the Dermatology slice of it.

Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Dermatology landscape →

Recently read out & awaiting topline — Dermatology

· 6

Phase 3 dermatology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Incyte Corporation	A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) Asset: Povorcitinib	NonSegmental Vitiligo	Active Not Recruiting	Q1 2026 2026-03-17	Completed · awaiting Updated 4mo ago	NCT06113471
Incyte Corporation	A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) Asset: Povorcitinib	NonSegmental Vitiligo	Active Not Recruiting	Q1 2026 2026-02-24	Completed · awaiting Updated 4mo ago	NCT06113445
Pfizer	A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo Asset: Ritlecitinib	Stable Nonsegmental Vitiligo +1	Completed	Q1 2026 2026-02-05	Completed · awaiting Updated 5mo ago	NCT05583526
Cassiopea SpA	A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss Asset: Clascoterone 5% solution	Alopecia, Androgenetic	Completed	Q1 2026 2026-01-26	Completed · awaiting Updated 4mo ago	NCT05910450
Ascletis Pharmaceuticals Co., Ltd.	A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris Asset: ASC40	Acne	Completed	Q4 2025 2025-11-12	Completed · awaiting Updated 8mo ago	NCT06248008
AbbVie	A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo Asset: Upadacitinib	Vitiligo	Active Not Recruiting	Q3 2025 2025-09-23	Completed · awaiting Updated 8mo ago	NCT06118411

Upcoming dermatology readouts — next 12 months

· 16

Industry Phase 3 dermatology trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Samson Clinical Operations Pty Ltd	Efficacy & Safety of Minoxidil SL Tablets in Men With AGA Asset: Minoxidil	Androgenetic Alopecia +1	Completed	Q3 2026 2026-07 (est.)	Estimated · aging Updated 12mo ago	NCT06924632
Incyte Corporation	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo Asset: Ruxolitinib Cream	NonSegmental Vitiligo	Recruiting	Q3 2026 2026-08-10 (est.)	Estimated · aging Updated 7mo ago	NCT06548360
AbbVie	ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars	Atrophic Acne Scars	Active Not Recruiting	Q3 2026 2026-08 (est.)	Estimated · stale Updated 13mo ago	NCT05995340
Applied Biology, Inc.	Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Asset: DA-007	Chemotherapy Induced Alopecia +1	Not Yet Recruiting	Q3 2026 2026-09-11 (est.)	Estimated · stale Updated 14mo ago	NCT06762548
Zhejiang Sunshine Mandi Pharmaceut…	Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris Asset: Clascoterone	Acne Vulgaris	Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 12mo ago	NCT06403501
Chong Kun Dang Pharmaceutical	A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia Asset: CKD-843 dose#1	Androgenetic Alopecia	Not Yet Recruiting	Q4 2026 2026-12-19 (est.)	Estimated · stale Updated 15mo ago	NCT06916793
Veradermics, Inc.	Safety and Efficacy of VDPHL01 in Males With AGA Asset: VDPHL01	Androgenetic Alopecia +2	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · fresh Updated 5mo ago	NCT06972264
Galderma R&D	A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris Asset: Trifarotene	Acne Vulgaris	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · aging Updated 8mo ago	NCT07186413
Eurofarma Laboratorios S.A.	Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris Asset: Placebo of the experimental drug	Acne Vulgaris +1	Not Yet Recruiting	Q1 2027 2027-02 (est.)	Estimated · stale Updated 15mo ago	NCT06905210
Pfizer	A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Asset: Ritlecitinib 100 mg	Alopecia Areata	Active Not Recruiting	Q1 2027 2027-03-09 (est.)	Estimated · aging Updated 10mo ago	NCT06873945
Applied Biology, Inc.	Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth Asset: DA-001	Telogen Effluvium +5	Not Yet Recruiting	Q1 2027 2027-03-19 (est.)	Estimated · fresh Updated 3mo ago	NCT06648850
Pfizer	A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata Asset: Ritlecitinib higher dose	Severe Alopecia Areata	Active Not Recruiting	Q2 2027 2027-04-20 (est.)	Estimated · fresh Updated 4mo ago	NCT07029711
Pfizer	A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo Asset: Ritlecitinib	Vitiligo	Active Not Recruiting	Q2 2027 2027-04-23 (est.)	Estimated · aging Updated 11mo ago	NCT06163326
Incyte Corporation	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo Asset: Ruxolitinib Cream	NonSegmental Vitiligo	Recruiting	Q2 2027 2027-04-30 (est.)	Estimated · aging Updated 7mo ago	NCT06804811
Sun Pharmaceutical Industries, Inc.	Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata Asset: CTP-543	Alopecia Areata	Active Not Recruiting	Q2 2027 2027-05 (est.)	Estimated · aging Updated 9mo ago	NCT03898479
Veradermics, Inc.	Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) Asset: VDPHL01 QD	Androgenetic Alopecia (AGA) +4	Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 8mo ago	NCT07146022

Unlock 11 more dermatology readouts · plus filters on the full calendar

Upgrade to Pro

About this calendar

Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.